155 related articles for article (PubMed ID: 35938884)
1. A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting.
Gong Q; Li X; Li T; Wu X; Hu J; Yang F; Zhang X
Angew Chem Int Ed Engl; 2022 Oct; 61(40):e202210001. PubMed ID: 35938884
[TBL] [Abstract][Full Text] [Related]
2. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
3. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
[TBL] [Abstract][Full Text] [Related]
5. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
[TBL] [Abstract][Full Text] [Related]
7. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
8. Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.
Ma X; Huang X; Huang G; Li L; Wang Y; Luo X; Boothman DA; Gao J
Adv Healthc Mater; 2014 Aug; 3(8):1210-6. PubMed ID: 24532286
[TBL] [Abstract][Full Text] [Related]
9. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
[TBL] [Abstract][Full Text] [Related]
10. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Li X; Liu Z; Zhang A; Han C; Shen A; Jiang L; Boothman DA; Qiao J; Wang Y; Huang X; Fu YX
Nat Commun; 2019 Jul; 10(1):3251. PubMed ID: 31324798
[TBL] [Abstract][Full Text] [Related]
11. Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy.
Li Y; Feng M; Guo T; Wang Z; Zhao Y
Adv Healthc Mater; 2023 Aug; 12(20):e2300349. PubMed ID: 36970948
[TBL] [Abstract][Full Text] [Related]
12. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
14. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
15. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
[TBL] [Abstract][Full Text] [Related]
16. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
17. A novel multifunctional nanoparticles formed by molecular recognition between AS1411 aptamer and redox-responsive paclitaxel-nucleoside analogue prodrug for combination treatment of β-lapachone and paclitaxel.
Chen X; Ji J; Zhou K; Fan X; Li L; Xu W
Colloids Surf B Biointerfaces; 2022 Apr; 212():112345. PubMed ID: 35074639
[TBL] [Abstract][Full Text] [Related]
18. Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
Wang K; Yang B; Ye H; Zhang X; Song H; Wang X; Li N; Wei L; Wang Y; Zhang H; Kan Q; He Z; Wang D; Sun J
ACS Appl Mater Interfaces; 2019 May; 11(21):18914-18922. PubMed ID: 31055911
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial activity is the key to the protective effect of β-Lapachone, a NAD
Lin SY; Syu JP; Lo YT; Chau YP; Don MJ; Shy HT; Lai SM; Kung HN
Phytomedicine; 2022 Jul; 101():154094. PubMed ID: 35447421
[TBL] [Abstract][Full Text] [Related]
20. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]